Abstract
Purpose: This phase I first-in-human trial evaluated salirasib, an S-prenyl derivative of thiosalicylic acid that competitively blocks RAS signaling. Methods: Patients with advanced cancers received salirasib twice daily for 21 days every 4 weeks. Doses were escalated from 100 to 200, 400, 600, and 800 mg. Results: The most common toxicity was dose-related diarrhea (Grade 1-2, 79% of 24 patients). Other toxicities included abdominal pain, nausea, and vomiting. No Grade 3-4 toxicity was noted. Nineteen (79%) patients had no drug-related toxicity >Grade 1. Dose-limiting toxicity (DLT) was not reached, but all three patients treated with 800 mg experienced Grade 1-2 diarrhea, abrogating dose escalation. Six patients were treated at a dose of 600 mg with no DLTs. Seven (29%) patients had stable disease on salirasib 4 months (range 4-23+). The salirasib pharmacokinetic profile was characterized by slow absorption and a rapid elimination phase following oral administration. Salirasib exposure (C max; day 1 AUCinf vs. day 15 AUC0-12 h) was similar between days 1 and 15 (P > 0.05). The T 1/2 (mean ± SD) was 3.6 ± 2.2 h on day 1. Conclusions: Salirasib therapy was well tolerated. The recommended dose for phase II studies is 600 mg twice daily.
Original language | English (US) |
---|---|
Pages (from-to) | 235-241 |
Number of pages | 7 |
Journal | Cancer Chemotherapy and Pharmacology |
Volume | 65 |
Issue number | 2 |
DOIs | |
State | Published - Jan 2010 |
Keywords
- FTS
- Pharmacokinetics
- Phase I
- Solid tumors
- Toxicity
ASJC Scopus subject areas
- Oncology
- Toxicology
- Pharmacology
- Cancer Research
- Pharmacology (medical)